Table 2.
Mean global HRQoL scores in patients with active AML, stratified by measurement tool
| Study | Subjects with active AML | |
|---|---|---|
| Baseline mean score | Endpoint mean score | |
| Cancer- or leukemia-specific instruments | ||
| EORTC QLQ-C30a | ||
| Moller 2012 | 56.2 | 77.2 |
| Oliva 2011 | 50 | – |
| FACT-G | ||
| Battaglini 2009 | 56.1 | 52.5 |
| Sekeres 2004 | 83 | 84 |
| FACT-Leu | ||
| Klepin 2010 | 106.2 | 127.5 |
| QOL-E | ||
| Oliva 2011 | 54 | – |
| Generic instruments | ||
| SF-12 or SF-36 physical | ||
| Sekeres 2004 | 32 | 29 |
| SF-12 or SF-36 mental | ||
| Sekeres 2004 | 53 | 52 |
AML acute myeloid leukemia, EORTC European Organization for Research and Treatment of Cancer, FACT Functional Assessment of Cancer Therapy, Leu leukemia, QLQ Quality of Life Questionnaire, QoL-E Qualita’ Della Vita Legata Alla Salute Nelle Sindromi Mielodisplastiche, SF short form
aSherman et al. utilized the EORTC QLQ-C30 instrument, but did not report mean/median values, and the study was not included in this table